Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 4/2006

01-08-2006 | Commentary

Etomidate, pharmacological adrenalectomy and the critically ill: a matter of vital importance

Authors: Roxanna Bloomfield, David W Noble

Published in: Critical Care | Issue 4/2006

Login to get access

Abstract

Etomidate is a potent suppressant of adrenal steroidogenesis, effectively inducing reversible pharmacological adrenalectomy. Recent evidence suggests that for every five patients with septic shock given etomidate without corticosteroid supplementation, one patient will die as a consequence. Other critically ill patients are also at possible risk, and this risk requires further exploration. Etomidate will also confound investigations into the effects of disease states on adrenal function, and should therefore be avoided. A moratorium on the use of etomidate in critically ill patients outside clinical trials may be prudent until its safety is established.
Literature
1.
Mohammad Z, Afessa B, Finkielman JD: The incidence of relative adrenal insufficiency in patients with septic shock after the administration of etomidate. Critical Care 2006, 10: R105. 10.1186/cc4979PubMedCentralCrossRefPubMed
2.
Bloomfield R, Noble DW: Etomidate and fatal outcome – even a single bolus dose may be detrimental for some patients [letter]. Br J Anaesth 2006, 97: 116-117. 10.1093/bja/ael124CrossRefPubMed
3.
Watt I, Ledingham I: Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984, 39: 973-981.CrossRefPubMed
4.
Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D: Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984, 310: 1415-1420.CrossRefPubMed
5.
Bloomfield R, Noble DW: Corticosteroids for septic shock – a standard of care? Br J Anaesth 2004, 93: 178-180. 10.1093/bja/aeh175CrossRefPubMed
6.
Reves JG, Glass PSA, Lubarsky DA, McEvoy MD: Intravenous nonopioid anesthetics. In Anesthesia. 6th edition. Edited by: Miller RD. Philadelphia, PA: Elsevier Churchill Livingston; 2005.
7.
8.
Malerba G, Romano-Girard F, Cravoisy A, Dousset A, Nace L, Lévy B, Bollaert P: Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005, 31: 388-392. 10.1007/s00134-004-2550-8CrossRefPubMed
9.
Den Brinker M, Joosten KFM, Liem O, de Jong FH, Hop WCJ, Hazelzet JA, van Dijk M, Hokken-Koelega ACS: Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomi-date on adrenal function and mortality. J Clin Endocrinol Metab 2005, 90: 5110-5117. 10.1210/jc.2005-1107CrossRefPubMed
10.
Annane D: Etomidate and intensive care physicians [letter]. Intensive Care Med 2005, 31: 1454. 10.1007/s00134-005-2755-5CrossRef
11.
Annane D, Sebille V, Charpentier C, Bollaert P, Francois B, Korach J, Capellier G, Cohen Y, Azoulay E, Troché G, et al.: Effect of treatment with low doses of hydrocortisone and flu-drocortisone on mortality in patients with septic shock. JAMA 2002, 288: 862-871. 10.1001/jama.288.7.862CrossRefPubMed
12.
Annane D: ICU physicians should abandon the use of etomi-date. Intensive Care Med 2005, 31: 325-326. 10.1007/s00134-005-2560-1CrossRefPubMed
13.
Bloomfield R, Noble D: Etomidate and intensive care physicians [letter]. Intensive Care Med 2005, 31: 1453. 10.1007/s00134-005-2754-6CrossRefPubMed
14.
Bloomfield R, Noble DW: Exploring the role of etomidate in septic shock and acute respiratory distress syndrome. Critical Care Med 2006, 34: 1858-1859. 10.1097/01.CCM.0000220066.85816.94CrossRef
15.
Zaloga GP, Marik P: Hypothalamic-pituitary-adrenal insufficiency. Crit Care Clin 2001, 17: 25-41. 10.1016/S0749-0704(05)70150-0CrossRefPubMed
Metadata
Title
Etomidate, pharmacological adrenalectomy and the critically ill: a matter of vital importance
Authors
Roxanna Bloomfield
David W Noble
Publication date
01-08-2006
Publisher
BioMed Central
Published in
Critical Care / Issue 4/2006
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc5020

Other articles of this Issue 4/2006

Critical Care 4/2006 Go to the issue

Review

Year in review 2005: Critical Care – nephrology

Research

Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding

Research

Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis

Research

Serum procalcitonin level and leukocyte antisedimentation rate as early predictors of respiratory dysfunction after oesophageal tumour resection

Research

Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective

Research

Extrapulmonary manifestations of severe respiratory syncytial virus infection – a systematic review